- Stock: Pre-Order
- Brand: Novo Nordisk
- Product ID: Insulin Degludec
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
This Item is for pre order
Tresiba FlexTouch 100 – Insulin Degludec 100 IU/ml by Novo Nordisk (5 Pens)
| Generic Name | Insulin Degludec (Tresiba) |
| Brand Name | Tresiba FlexTouch 100 |
| Manufacturer | Novo Nordisk A/S (Denmark) |
| Dosage Form | Solution for Injection — Pre-filled FlexTouch Pen (3 ml) |
| Strength | 100 IU/ml |
| Pack Size | 5 FlexTouch Pens × 3 ml = 1,500 IU total |
| Drug Class | Ultra-Long-Acting Basal Insulin Analogue |
| Prescription Required | Yes — Rx Only |
| Duration of Action | Beyond 42 hours (ultra-long, flat peakless profile) |
What is Tresiba FlexTouch 100?
Tresiba FlexTouch 100 is the 5-pen pack of insulin degludec 100 IU/ml — Novo Nordisk's ultra-long-acting basal insulin analogue. It provides once-daily basal coverage for beyond 42 hours with a flat, peakless glucose-lowering effect. The proprietary FlexTouch pen delivers doses in 1-unit increments from 1 to 80 IU with minimal injection force. Degludec's multi-hexamer depot technology offers unprecedented pharmacokinetic stability, resulting in significantly lower day-to-day glucose variability and less nocturnal hypoglycaemia compared to insulin glargine U100. Suitable for Type 1 and Type 2 diabetes in adults, adolescents, and children ≥1 year.
Generic Name & Composition
Each ml: 100 IU insulin degludec. Degludec molecules form soluble multi-hexamers in the SC depot via zinc coordination. Gradual zinc loss causes hexamer dissociation → monomer absorption into capillaries. This prolonged release mechanism produces a half-life of ~25 hours and an action duration >42 hours with minimal peak — markedly different from the 20–24-hour profiles of glargine or detemir.
Indications
- Type 1 diabetes — basal component in basal-bolus insulin regimen
- Type 2 diabetes — once-daily basal insulin; combination with OADs or bolus insulin
- Insulin-naïve patients transitioning to basal insulin
- Adults, adolescents, and children ≥1 year requiring long-acting basal insulin
How It Works — Mechanism of Action
After SC injection, degludec forms a depot of soluble multi-hexamers. Zinc ions stabilise the complexes; as zinc slowly diffuses away, di-hexamers and monomers separate and absorb into the bloodstream. This step-rate-limited absorption creates a smooth, flat plasma profile with no pronounced peak — providing sustained, predictable basal insulin activity throughout the day and night.
Dosage & Administration
Type 2 (insulin-naïve): Start 10 IU once daily; titrate by 2 IU every 3 days targeting fasting BG. Type 1: Individualised basal dose replacement. Flexible dosing: May be injected at any time of day — if a time change is needed, ensure ≥8 hrs between doses. Inject subcutaneously (abdomen, thigh, or upper arm). Do not administer IV or IM. Do not mix with other insulins.
Side Effects
Very common: Hypoglycaemia — rates lower than glargine U100 in major clinical trials.
Common: Injection site reactions, lipohypertrophy, peripheral oedema, weight gain.
Uncommon: Lipoatrophy, visual refraction changes at initiation.
Rare: Generalised hypersensitivity, anaphylaxis.
Drug Interactions
Enhance hypoglycaemic effect: OADs, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, sulfonamides, salicylates, alcohol.
Reduce effect: Corticosteroids, glucagon, thyroid hormones, growth hormone, sympathomimetics, danazol, thiazides, oral contraceptives.
Mask hypoglycaemia symptoms: Beta-blockers, clonidine, reserpine.
Contraindications
- Hypersensitivity to insulin degludec or any excipient
- Hypoglycaemia (active episode); IV or IM administration
Pregnancy & Lactation
Pregnancy: Limited clinical data. Under specialist supervision, may be considered. Lactation: Clinically insignificant amounts expected in breast milk; unlikely to affect breastfed infant.
Precautions & Warnings
- Missed dose: Inject when remembered; ensure ≥8 hrs until next dose. Resume normal schedule next day.
- Do not mix degludec with any other insulin in the same pen or syringe.
- Rotate injection sites to prevent lipohypertrophy.
- Renal/hepatic impairment: May require dose reduction — monitor closely.
Overdose
Results in hypoglycaemia. Mild-moderate: oral glucose/carbohydrates. Severe: IV 20% dextrose or IM glucagon 1 mg. Given degludec's prolonged duration (>42 hrs), sustained glucose monitoring post-overdose is essential.
Storage Instructions
- Unopened: 2–8°C in refrigerator. Do not freeze.
- In-use pen: Store below 30°C. Do not refrigerate. Do not expose to direct sunlight.
- Discard 56 days after first use — longer than most basal insulin pens.
Frequently Asked Questions (FAQs)
Q1: What is the difference between Tresiba 100 and Tresiba 200?
Tresiba 100 contains 100 IU/ml — suitable for doses up to 80 IU per injection (FlexTouch max). Tresiba 200 (U200) contains 200 IU/ml, allowing up to 160 IU in a single 3 ml pen — designed for insulin-resistant patients requiring high doses. Both deliver the same degludec molecule with identical clinical efficacy per unit.
Q2: How long does Tresiba last compared to Lantus or Levemir?
Tresiba: >42 hours. Lantus (glargine U100): ~24 hours. Levemir (detemir): 16–24 hours. Tresiba's ultra-long duration provides more stable basal coverage and lower glycaemic variability than either comparator.
Q3: Can Tresiba FlexTouch 100 be used in children?
Yes. Tresiba 100 IU/ml is approved for children ≥1 year. The U200 formulation is only approved for adults. Dosing should be under paediatric endocrinology guidance.
Q4: Is the 5-pen pack more economical than the single pen?
Yes. Tresiba FlexTouch 100 (5×3ml) provides 1,500 IU — five times the single pen's 300 IU — at a lower per-unit cost, making it the preferred option for regular users.
⚕ Medical Disclaimer: For educational purposes only. Tresiba is Rx-only. Consult your diabetologist before changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy.
